BioMed News Bytes: NicOx, Allos, Pressure BioSciences, YM BioSciences
September 25, 2009 | about: ALTH / IGK / NICXF.PK / PBIO / YMI
Font Size: Print EmailTweetThis
On 5/19/09, NicOx (NICXF.PK) announced that quality of life and utility results from its first Phase 3 clinical trial for naproxcinod were presented at the International Society For Pharmacoeconomics and Outcomes Research Annual International Meeting in Orlando, FL. Naproxcinod is a novel type of anti-inflammatory agent, which completed a Phase 3 clinical program last year in patients with osteoarthritis.
The drug is designed to have an improved side effect profile (including a neutral effect on blood pressure) as compared to a standard dose of the widely used NSAID drug naproxen. Naproxcinod has completed three pivotal Phase 3 studies with positive results. On 9/25/09, NicOx submitted a NDA for naproxcinod to the FDA for an estimated decision date of 7/25/10 for a standard, 10-month review.